You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute

Article metrics

Article menu

Download PDFPDF

Research Article
High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute

 

Online download statistics by month:

Online download statistics by month: December 2019 to September 2025

AbstractFullPdf
Dec 2019220
Jan 2020550
Feb 202019193
Mar 202015155
Apr 202017172
May 2020454524
Jun 202018182
Jul 202013132
Aug 2020663
Sep 202025254
Oct 202028284
Nov 202033336
Dec 202016163
Jan 202119193
Feb 202128284
Mar 20211041043
Apr 202119197
May 202112126
Jun 2021661
Jul 202111113
Aug 202113122
Sep 202117177
Oct 202116164
Nov 202119194
Dec 202119193
Jan 202218195
Feb 202217176
Mar 202217185
Apr 202225265
May 202243455
Jun 202238393
Jul 202231324
Aug 202228285
Sep 2022262612
Oct 202226263
Nov 2022252615
Dec 202222222
Jan 202322223
Feb 202357576
Mar 202333357
Apr 202318194
May 202310105
Jun 202320202
Jul 202316165
Aug 202322228
Sep 202320205
Oct 202338388
Nov 202371713
Dec 20232282288
Jan 2024313213
Feb 202425258
Mar 2024313220
Apr 2024252510
May 202418187
Jun 202436359
Jul 2024495012
Aug 2024272510
Sep 2024535315
Oct 2024323217
Nov 202423246
Dec 2024323213
Jan 2025303010
Feb 2025242414
Mar 2025333410
Apr 2025959524
May 2025313125
Jun 202520217
Jul 2025110
Aug 2025110
Sep 2025110
Total20142027469